PR NewsWire

Umowa dotyczy mobilnej narracyjnej gry fabularnej Harry Potter: Hogwarts Mystery osadzonej w Szkole Magii i Czarodziejstwa w Hogwarcie.
<p>Oparta na opowieści gra mobilna RPG daje fanom możliwość wybrania własnej ścieżki w charakterze ucznia w Szkole Magii i Czarodziejstwa w Hogwarcie.

Not intended for U.K./U.S. based media
<p>- First treatment in relapsing-remitting multiple sclerosis (RRMS) to show sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years,
<p>- Updated registration follows recent approval of Mavenclad in Europe and Canada.

- First oral short-course treatment for relapsing
<p>- remitting multiple sclerosis (RRMS) now approved in Canada, which has one of the highest rates of MS in the world (1);
<p>- Mavencladhas shown sustained clinical efficacy with a duration of oral treatment of 20 days over 2 years;
<p>- The approval of Mavenclad by Health Canada follows the recent approval of Mavenclad across Europe by the European Commission.